ANVS 8-K SEC Filing Analysis

Latest settled — T+5d

ANVS ▲ +0.49% at T+5d

NEUTRAL call ✓ call won +0.49% · α vs SPY -1.13% · entry $2.05 → $2.06

Next anchor: T+20d in 3h

Last close $1.78 (close Jun 12) · -13.17% from $2.05 entry

Entry anchored
May 15, 03:59 PM ET
via Databento tick

T+1d

-5.37%

call -5.37% · α -4.72%

$1.94

settled 28d ago

T+5d

+0.49%

call +0.49% · α -1.13%

$2.06

settled 24d ago

T+20d

—

call — · α —

—

in 3h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Annovis Bio reported Q1 2026 results showing increased net loss per share ($0.63 vs $0.32) and cash burn, but highlighted strong enrollment progress in its pivotal Phase 3 Alzheimer's trial (85% enrolled) and Parkinson's open-label extension study (40% enrolled), along with a positive DSMB recommendation. The clinical milestones support the NDA timeline but financial deterioration is a concern.

Actionable Insight

The clinical progress is positive but expected; cash runway remains tight despite the recent $10M offering. Watch for enrollment completion and top-line data in early 2027, which are the primary catalysts. The increased loss rate keeps dilution risk alive.

Key Facts

Phase 3 AD trial enrollment at 85%; full enrollment on track for summer 2026
PD OLE study enrollment at 40%; full enrollment expected Q4 2026
Positive DSMB recommendation for buntanetap safety at 6 months
Net loss per share widened to $0.63 from $0.32 in Q1 2025
Cash and equivalents $14.2M as of March 31, 2026, plus $10M April direct offering
NDA submission for symptomatic AD treatment expected early 2027

Financial Impact

Net loss increased to $17.6M from $5.5M year-over-year; cash burn accelerated due to Phase 3 trial costs

net loss per sharecash and equivalentsoperating expenses

Risk Factors

Clinical trial failure or data miss could devastate stock
Cash burn may require additional dilutive financing before data readout
Regulatory path for NDA uncertain until Phase 3 results

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-062451
Document: tm2614822d1_8k.htm	0001104659-26-062451
Document: 0001104659-26-062451-index-headers.html	0001104659-26-062451
Document: 0001104659-26-062451-index.html	0001104659-26-062451
Document: 0001104659-26-062451.txt	0001104659-26-062451
8-K Data (Synthetic)	0001104659-26-062451

7 reports for ANVS

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+5▲ +11.63%May 20, 2026

Filters

Reports for ANVS — sortable, filterable
	Type				Now
May 20, 2026 25d ago	424B5 BEARISH ★ 6/10	$2.15 $1.90	▲ +11.63%	▲ +13.23%	$1.78 (+17.21%)
May 19, 2026 26d ago	424B5 BEARISH ★ 7/10	$2.04 $2.01	▲ +1.47%	▲ +2.71%	$1.78 (+12.75%)
May 15, 2026 4w ago	8-K MIXED ★ 5/10	$2.05 $2.06	▲ +0.49%	▼ −1.13%	$1.78 (−13.17%)
May 15, 2026 4w ago	Press Release BEARISH ★ 6/10	$2.06 $2.23	▼ −8.25%	▼ −7.29%	$1.78 (+13.59%)
Apr 10, 2026 9w ago	Press Release MIXED ★ 6/10	$1.59 $1.87	▲ +17.61%	▲ +13.11%	$1.78 (+11.95%)
Mar 19, 2026 12w ago	Press Release NEUTRAL ★ 4/10	$2.67 $2.15	▼ −19.48%	▼ −17.26%	$1.78 (−33.33%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$2.83 $2.50	▼ −11.66%	▼ −9.62%	$1.78 (−37.10%)

US Market Status

Market Closed — Opens in 4h 40m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access